Inhibikase Therapeutics Reports Q3 2026 Results, Highlights Phase 3 Trial Progress

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced its financial results for the quarter ended September 30, 2026, and provided an update on the clinical development of its lead candidate, IKT-001. The company reported a net loss of $20.5 million for the quarter, compared to a net loss of $11.9 million in the same period the previous year. For the nine months ended September 30, 2026, the net loss totaled $56.4 million, or $0.31 per share, compared to $35.5 million, or $0.40 per share, for the prior year period.

Research and development expenses for the third quarter of 2026 were $15.0 million, up from $7.6 million in the prior year quarter. The company noted that the increase was driven by costs associated with the acquisition of CorHepta in February 2025, including a non-cash write-off of in-process research and development of $7.4 million and stock-based compensation expense of $1.8 million. Selling, general, and administrative expenses for the quarter were $7.2 million.

As of September 30, 2026, Inhibikase held $193.3 million in cash, cash equivalents, and marketable securities. The company stated that this capital position, combined with the proceeds from a $50 million equity raise in July 2026, is expected to fund operations through the topline data readout of Part B in the ongoing Phase 3 study.

In terms of clinical development, the company highlighted progress on the global Phase 3 IMPROVE-PAH study. As of November 2026, regulatory approvals for the trial have been obtained in 28 countries globally, with 79 of a planned 180 clinical sites activated. The study is a two-part adaptive trial. Part A is a double-blind, placebo-controlled study in approximately 140 patients with a primary endpoint of change in Pulmonary Vascular Resistance at Week 24. Part B, which begins following the enrollment of the last patient in Part A, is a study in approximately 346 patients with a primary endpoint of change in 6-minute walk distance at Week 24. An interim safety readout for Part A is planned for the first half of 2027.

The company also noted recent corporate developments, including the appointment of Scott M. Wasserman, MD, to the Board of Directors in October 2026. Additionally, in July 2026, the FDA’s Office of Orphan Products Development granted Orphan Drug Designation for IKT-001.